Atara Biotherapeutics (ATRA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $9.18, -4.87% vs the prior close of $9.65.
- Volume 19.49K shares, 0.4x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ATRA slides 4.9% to $9.18. Closed at $9.18, -4.87% vs the prior close of $9.65. Day range $9.18–$9.90, opened at $9.65.
ATRA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ATRA slides 4.9% to $9.18
- Closed at $9.18, -4.87% vs the prior close of $9.65. Day range $9.18–$9.90, opened at $9.65.
- Volume was 19.49K shares, 0.4x its 50-day average of 45.65K — lighter than usual.
- Price is -0.3% vs its 50-day average ($9.21) and +16.5% vs its 200-day average ($7.88).
- 52-week range $3.92–$19.15; today's close sits at 35% of that range, 52.1% below the 52-week high.
Oct 15, 2026 — ATRA rises 0.9% to $9.65
- Closed at $9.65, +0.94% vs the prior close of $9.56. Day range $9.19–$9.78, opened at $9.35.
- Volume was 24.30K shares, 0.5x its 50-day average of 45.81K — lighter than usual.
- Price is +5.0% vs its 50-day average ($9.19) and +21.8% vs its 200-day average ($7.93).
- 52-week range $3.92–$19.15; today's close sits at 38% of that range, 49.6% below the 52-week high.
Oct 14, 2026 — ATRA rises 2.7% to $9.56
- Closed at $9.56, +2.74% vs the prior close of $9.31. Day range $9.20–$9.99, opened at $9.29.
- Volume was 39.60K shares, 0.9x its 50-day average of 45.87K.
- Price is +4.3% vs its 50-day average ($9.17) and +20.0% vs its 200-day average ($7.97).
- 52-week range $3.92–$19.15; today's close sits at 37% of that range, 50.1% below the 52-week high.
Oct 13, 2026 — ATRA dips 0.8% to $9.31
- Closed at $9.31, -0.80% vs the prior close of $9.38. Day range $8.80–$9.54, opened at $9.25.
- Volume was 32.30K shares, 0.7x its 50-day average of 46.28K.
- Price is +1.7% vs its 50-day average ($9.15) and +16.2% vs its 200-day average ($8.01).
- 52-week range $3.92–$19.15; today's close sits at 35% of that range, 51.4% below the 52-week high.
Oct 12, 2026 — ATRA dips 1.1% to $9.38
- Closed at $9.38, -1.05% vs the prior close of $9.48. Day range $8.99–$9.58, opened at $9.42.
- Volume was 26.80K shares, 0.6x its 50-day average of 46.44K — lighter than usual.
- Price is +2.7% vs its 50-day average ($9.14) and +16.6% vs its 200-day average ($8.05).
- 52-week range $3.92–$19.15; today's close sits at 36% of that range, 51.0% below the 52-week high.
Oct 9, 2026 — ATRA rises 2.7% to $9.48
- Closed at $9.48, +2.71% vs the prior close of $9.23. Day range $9.33–$9.56, opened at $9.33.
- Volume was 22.10K shares, 0.5x its 50-day average of 47.92K — lighter than usual.
- Price is +4.0% vs its 50-day average ($9.12) and +17.2% vs its 200-day average ($8.09).
- 52-week range $3.92–$19.15; today's close sits at 37% of that range, 50.5% below the 52-week high.
Oct 8, 2026 — ATRA dips 1.5% to $9.23
- Closed at $9.23, -1.49% vs the prior close of $9.37. Day range $8.82–$9.42, opened at $9.42.
- Volume was 28.90K shares, 0.6x its 50-day average of 48.13K.
- Price is +1.5% vs its 50-day average ($9.09) and +13.5% vs its 200-day average ($8.13).
- 52-week range $3.92–$19.15; today's close sits at 35% of that range, 51.8% below the 52-week high.
Oct 7, 2026 — ATRA slides 3.9% to $9.37
- Closed at $9.37, -3.90% vs the prior close of $9.75. Day range $9.37–$9.75, opened at $9.62.
- Volume was 11.40K shares, 0.2x its 50-day average of 49.61K — lighter than usual.
- Price is +3.4% vs its 50-day average ($9.07) and +14.7% vs its 200-day average ($8.17).
- 52-week range $3.92–$19.15; today's close sits at 36% of that range, 51.1% below the 52-week high.
Oct 6, 2026 — ATRA jumps 3.7% to $9.75
- Closed at $9.75, +3.72% vs the prior close of $9.40. Day range $9.05–$9.79, opened at $9.41.
- Volume was 47.60K shares, 1.0x its 50-day average of 49.92K.
- Price is +7.9% vs its 50-day average ($9.03) and +18.8% vs its 200-day average ($8.21).
- 52-week range $3.92–$19.15; today's close sits at 38% of that range, 49.1% below the 52-week high.
Oct 5, 2026 — ATRA dips 0.8% to $9.40
- Closed at $9.40, -0.84% vs the prior close of $9.48. Day range $8.95–$9.63, opened at $9.59.
- Volume was 39.30K shares, 0.8x its 50-day average of 50.63K.
- Price is +4.5% vs its 50-day average ($8.99) and +14.0% vs its 200-day average ($8.25).
- 52-week range $3.92–$19.15; today's close sits at 36% of that range, 50.9% below the 52-week high.
Oct 2, 2026 — ATRA jumps 12.1% to $9.48
- Closed at $9.48, +12.06% vs the prior close of $8.46. Day range $8.25–$9.68, opened at $8.46.
- Volume was 85.70K shares, 1.7x its 50-day average of 49.85K.
- Price is +5.8% vs its 50-day average ($8.96) and +14.4% vs its 200-day average ($8.29).
- 52-week range $3.92–$19.15; today's close sits at 37% of that range, 50.5% below the 52-week high.
ATRA latest news & SEC filings
Every SEC filing by or about ATRA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cherry Brian N bought 104,166 shares at $9.60 (≈$999.99K) on Sep 4, 2026
- Cherry Brian N bought 104,166 shares at $9.60 (≈$999.99K) on Sep 4, 2026
- Cherry Brian N bought 104,166 shares at $9.60 (≈$999.99K) on Sep 4, 2026
- Cherry Brian N bought 104,166 shares at $9.60 (≈$999.99K) on Sep 4, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 26, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 26, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Nguyen Anhco sold 5,062 shares at $8.08 (≈$40.90K) on Aug 17, 2026
- Nguyen Anhco sold 5,062 shares at $8.08 (≈$40.90K) on Aug 17, 2026
- Nguyen Anhco sold 5,062 shares at $8.08 (≈$40.90K) on Aug 17, 2026
- Nguyen Anhco sold 5,062 shares at $8.08 (≈$40.90K) on Aug 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $630.00K (prior year $17.57M) (-96.4% vs Jun 30, 2025)
- Net income: -$4.83M (prior year $2.39M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.32 (prior year $0.19) (loss widened vs Jun 30, 2025)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 24, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 6, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jun 26, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Things to know before you trade ATRA
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: Mar 16, 2026, Jan 12, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.28% (largest 12.1%). That is a volatile stock.
- Liquidity: about 36.35K shares (≈$333.74K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $9.18 vs a range of $3.92–$19.15 (35% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 5 open-market buys, 20 sales; latest: Brian N Cherry bought 104,166 shares on Sep 4, 2026.
- Latest filings: 10-Q Aug 12, 2026; 8-K Aug 12, 2026; 8-K Jun 26, 2026.
- Share count: 10.04M shares outstanding (Aug 10, 2026), +42.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
ATRA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 9.65 | 9.90 | 9.18 | 9.18 | 19.49K |
| Oct 15, 2026 | 9.35 | 9.78 | 9.19 | 9.65 | 24.30K |
| Oct 14, 2026 | 9.29 | 9.99 | 9.20 | 9.56 | 39.60K |
| Oct 13, 2026 | 9.25 | 9.54 | 8.80 | 9.31 | 32.30K |
| Oct 12, 2026 | 9.42 | 9.58 | 8.99 | 9.38 | 26.80K |
| Oct 9, 2026 | 9.33 | 9.56 | 9.33 | 9.48 | 22.10K |
| Oct 8, 2026 | 9.42 | 9.42 | 8.82 | 9.23 | 28.90K |
| Oct 7, 2026 | 9.62 | 9.75 | 9.37 | 9.37 | 11.40K |
| Oct 6, 2026 | 9.41 | 9.79 | 9.05 | 9.75 | 47.60K |
| Oct 5, 2026 | 9.59 | 9.63 | 8.95 | 9.40 | 39.30K |
| Oct 2, 2026 | 8.46 | 9.68 | 8.25 | 9.48 | 85.70K |
| Oct 1, 2026 | 8.73 | 9.20 | 8.23 | 8.46 | 90.90K |
| Sep 30, 2026 | 8.08 | 8.71 | 7.83 | 8.50 | 29.30K |
| Sep 29, 2026 | 8.33 | 8.82 | 7.89 | 8.05 | 56.40K |
| Sep 28, 2026 | 8.69 | 8.70 | 8.34 | 8.37 | 23.50K |
| Sep 25, 2026 | 8.60 | 8.99 | 8.53 | 8.81 | 31.20K |
| Sep 24, 2026 | 8.60 | 8.86 | 8.33 | 8.54 | 20.80K |
| Sep 23, 2026 | 8.92 | 8.95 | 8.40 | 8.56 | 40.50K |
| Sep 22, 2026 | 9.30 | 9.60 | 8.93 | 8.93 | 27.30K |
| Sep 21, 2026 | 9.69 | 9.92 | 9.30 | 9.38 | 29.70K |
About Atara Biotherapeutics
Atara Biotherapeutics (ATRA) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in THOUSAND OAKS, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1604464.
ATRA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Brian N Cherry | Director | Sep 4, 2026 |
| Gregory Austin Ciongoli | See Remarks | Jun 11, 2026 |
| Matthew K Fust | Director | Jun 11, 2026 |
| Jeremy Green | Director | Jul 24, 2026 |
| William K Heiden | Director | Jun 11, 2026 |
| James Huang | Director | May 11, 2026 |
| Anhco Nguyen | President and CEO | Aug 26, 2026 |
| Group, Llc Redmile | Director | Jul 24, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Yanina Grant-Huerta | Chief Accounting Officer | May 20, 2026 |
| Anhco Nguyen | President and CEO | Aug 26, 2026 |
| Kevin G Sarney | Interim CFO | Jul 6, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 4, 2026 | Brian N Cherry | Buy | 104,166 | $9.60 |
| Sep 4, 2026 | Brian N Cherry | Buy | 104,166 | $9.60 |
| Sep 4, 2026 | Brian N Cherry | Buy | 104,166 | $9.60 |
| Sep 4, 2026 | Brian N Cherry | Buy | 104,166 | $9.60 |
| Aug 17, 2026 | Anhco Nguyen | Sale | 5,062 | $8.08 |
| Aug 17, 2026 | Anhco Nguyen | Sale | 5,062 | $8.08 |
| Aug 17, 2026 | Anhco Nguyen | Sale | 5,062 | $8.08 |
| Aug 17, 2026 | Anhco Nguyen | Sale | 5,062 | $8.08 |
| May 18, 2026 | Anhco Nguyen | Sale | 5,241 | $9.13 |
| May 18, 2026 | Anhco Nguyen | Sale | 5,241 | $9.13 |
| May 18, 2026 | Anhco Nguyen | Sale | 5,241 | $9.13 |
| May 18, 2026 | Anhco Nguyen | Sale | 5,241 | $9.13 |
| May 18, 2026 | Yanina Grant-Huerta | Sale | 2,414 | $9.13 |
| May 18, 2026 | Yanina Grant-Huerta | Sale | 2,414 | $9.13 |
| May 18, 2026 | Yanina Grant-Huerta | Sale | 2,414 | $9.13 |
ATRA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $120.77M | $32.69M | 2.57 | $-50.94M |
| Dec 31, 2024 | $128.94M | $-85.40M | -11.41 | $-68.72M |
| Dec 31, 2023 | $8.57M | $-276.13M | -65.19 | $-192.98M |
| Dec 31, 2022 | — | $-228.30M | -2.24 | $-270.43M |
| Dec 31, 2021 | — | $-340.14M | -3.63 | $-220.52M |
Latest balance sheet: total assets $21.02M, total liabilities $58.02M, cash $3.22M (as of Jun 30, 2026).
ATRA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $9.23 |
| Mar 16, 2026 | 8-K Item 2.02 (results) | $5.87 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $5.88 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $12.47 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $10.32 |
| Jul 14, 2025 | 8-K Item 2.02 (results) | $9.30 |
| May 15, 2025 | 8-K Item 2.02 (results) | $7.61 |
| Mar 7, 2025 | 8-K Item 2.02 (results) | $6.90 |
| Jan 16, 2025 | 8-K Item 2.02 (results) | $7.83 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $11.67 |
| Aug 12, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ATRA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.